Murugesan Vanangamudi

645 total citations
23 papers, 498 citations indexed

About

Murugesan Vanangamudi is a scholar working on Infectious Diseases, Organic Chemistry and Molecular Biology. According to data from OpenAlex, Murugesan Vanangamudi has authored 23 papers receiving a total of 498 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Infectious Diseases, 9 papers in Organic Chemistry and 9 papers in Molecular Biology. Recurrent topics in Murugesan Vanangamudi's work include HIV/AIDS drug development and treatment (10 papers), HIV Research and Treatment (8 papers) and Synthesis and biological activity (4 papers). Murugesan Vanangamudi is often cited by papers focused on HIV/AIDS drug development and treatment (10 papers), HIV Research and Treatment (8 papers) and Synthesis and biological activity (4 papers). Murugesan Vanangamudi collaborates with scholars based in India, Germany and United States. Murugesan Vanangamudi's co-authors include S. B. Katti, Vigneshwaran Namasivayam, Sonali Kurup, Siddappa N. Byrareddy, Victor G. Kramer, Peng Zhan, Jacob Kongsted, Yenamandra S. Prabhakar, Xinyong Liu and Ravindra K. Rawal and has published in prestigious journals such as Journal of Medicinal Chemistry, Drug Discovery Today and Current Medicinal Chemistry.

In The Last Decade

Murugesan Vanangamudi

23 papers receiving 487 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Murugesan Vanangamudi India 12 234 227 172 121 82 23 498
Shenghua Gao China 11 185 0.8× 148 0.7× 100 0.6× 148 1.2× 69 0.8× 37 426
Gladys Mbemba France 13 205 0.9× 234 1.0× 173 1.0× 202 1.7× 51 0.6× 19 536
Giuliana Cuzzucoli Crucitti Italy 12 244 1.0× 201 0.9× 163 0.9× 217 1.8× 60 0.7× 20 499
Norman M. Gray United Kingdom 8 219 0.9× 78 0.3× 133 0.8× 230 1.9× 102 1.2× 12 505
Yuan Chu China 4 193 0.8× 42 0.2× 113 0.7× 102 0.8× 55 0.7× 7 376
Antonella De Montis Italy 12 197 0.8× 258 1.1× 115 0.7× 173 1.4× 113 1.4× 24 548
Guang‐Jin Im South Korea 11 252 1.1× 74 0.3× 246 1.4× 149 1.2× 61 0.7× 14 461
Da Feng China 15 417 1.8× 220 1.0× 322 1.9× 172 1.4× 232 2.8× 31 592
Zhao Dang United States 10 95 0.4× 92 0.4× 84 0.5× 228 1.9× 42 0.5× 11 392

Countries citing papers authored by Murugesan Vanangamudi

Since Specialization
Citations

This map shows the geographic impact of Murugesan Vanangamudi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Murugesan Vanangamudi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Murugesan Vanangamudi more than expected).

Fields of papers citing papers by Murugesan Vanangamudi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Murugesan Vanangamudi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Murugesan Vanangamudi. The network helps show where Murugesan Vanangamudi may publish in the future.

Co-authorship network of co-authors of Murugesan Vanangamudi

This figure shows the co-authorship network connecting the top 25 collaborators of Murugesan Vanangamudi. A scholar is included among the top collaborators of Murugesan Vanangamudi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Murugesan Vanangamudi. Murugesan Vanangamudi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vanangamudi, Murugesan, et al.. (2024). Anticancer Therapy with Proteolysis-targeting Chimeras [PROTACs] Targeting the Tumor-microenvironment: Development, Current State and Prospects. Current Cancer Therapy Reviews. 21(4). 443–461. 1 indexed citations
2.
Anitha, Kuttiappan, et al.. (2024). Hepatoprotective effect of flavonoid rich fraction of Sesbania grandiflora: Results of In vivo, in vitro, and molecular docking studies. Journal of Ayurveda and Integrative Medicine. 15(5). 101036–101036. 1 indexed citations
3.
Vanangamudi, Murugesan, Palaniappan Senthilkumar, M. K. Kathiravan, & Vigneshwaran Namasivayam. (2023). Strategies in the Design and Development of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs). Viruses. 15(10). 1992–1992. 8 indexed citations
4.
Namasivayam, Vigneshwaran, Palaniappan Senthilkumar, & Murugesan Vanangamudi. (2022). Repurposing drugs targeting epidemic viruses. Drug Discovery Today. 27(7). 1874–1894. 7 indexed citations
5.
Palei, Narahari N., et al.. (2022). Systemic Optimization and Validation of RP-HPLC Method for the Estimationof Ritonavir from Hybrid Polymeric Nanoparticles in Rat Plasma. Current Pharmaceutical Analysis. 18(6). 650–662. 3 indexed citations
6.
Vanangamudi, Murugesan, et al.. (2022). Hydroxytriazenes incorporating sulphonamide derivatives: evaluation of antidiabetic, antioxidant, anti-inflammatory activities, and computational study. Molecular Diversity. 27(1). 223–237. 6 indexed citations
7.
Hassam, Mohammad, Murugesan Vanangamudi, Siddharth Sharma, et al.. (2021). Novel naphthyl based 1,2,4-trioxanes: Synthesis and in vivo efficacy in the Plasmodium yoelii nigeriensis in Swiss mice. Bioorganic & Medicinal Chemistry Letters. 51. 128372–128372. 7 indexed citations
8.
Vanangamudi, Murugesan, Sonali Kurup, & Vigneshwaran Namasivayam. (2020). Non-nucleoside reverse transcriptase inhibitors (NNRTIs): a brief overview of clinically approved drugs and combination regimens. Current Opinion in Pharmacology. 54. 179–187. 31 indexed citations
9.
Sharma, Poonam, et al.. (2020). Synthesis, antidiabetic, antioxidant and anti-inflammatory activities of novel hydroxytriazenes based on sulpha drugs. Heliyon. 6(8). e04787–e04787. 21 indexed citations
10.
11.
Malviya, Bhanwar Kumar, Pradeep Jaiswal, Ved Prakash Verma, et al.. (2019). Catalyst- and Solvent-Free Coupling of 2-Methyl Quinazolinones and Isatins: An Environmentally Benign Access of Diastereoselective Schizocommunin Analogues. ACS Omega. 4(7). 12146–12155. 8 indexed citations
12.
Namasivayam, Vigneshwaran, Murugesan Vanangamudi, Victor G. Kramer, et al.. (2018). The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic. Journal of Medicinal Chemistry. 62(10). 4851–4883. 146 indexed citations
13.
Kaur, Amandeep, et al.. (2018). Synthesis, Antitubercular Activity, Molecular Modeling and Docking Studies of Novel Thiazolidin-4-One Linked Dinitrobenzamide Derivatives. Current Bioactive Compounds. 16(1). 64–71. 1 indexed citations
14.
Vanangamudi, Murugesan, Vasanthanathan Poongavanam, & Vigneshwaran Namasivayam. (2017). HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: SAR and Lead Optimization Using CoMFA and CoMSIA Studies (1995-2016). Current Medicinal Chemistry. 24(34). 3774–3812. 10 indexed citations
15.
Suryawanshi, Rahul, Dipen Desai, Devidas N. Chaturbhuj, et al.. (2017). Evaluation of 4-thiazolidinone derivatives as potential reverse transcriptase inhibitors against HIV-1 drug resistant strains. Bioorganic Chemistry. 71. 211–218. 38 indexed citations
16.
Vanangamudi, Murugesan, Rahul Suryawanshi, Reshu Saxena, et al.. (2014). Rational design and synthesis of novel thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorganic & Medicinal Chemistry. 22(12). 3159–3170. 31 indexed citations
17.
Rawal, Ravindra K., Murugesan Vanangamudi, & S. B. Katti. (2012). Structure-Activity Relationship Studies on Clinically Relevant HIV-1 NNRTIs. Current Medicinal Chemistry. 19(31). 5364–5380. 33 indexed citations
18.
Vanangamudi, Murugesan, Reshu Saxena, Rajkamal Tripathi, et al.. (2011). Lead optimization at C-2 and N-3 positions of thiazolidin-4-ones as HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorganic & Medicinal Chemistry. 19(22). 6919–6926. 31 indexed citations
19.
Vanangamudi, Murugesan, Nidhi Sethi, Yenamandra S. Prabhakar, & S. B. Katti. (2010). CoMFA and CoMSIA of diverse pyrrolidine analogues as dipeptidyl peptidase IV inhibitors: active site requirements. Molecular Diversity. 15(2). 457–466. 11 indexed citations
20.
Vanangamudi, Murugesan, Yenamandra S. Prabhakar, & S. B. Katti. (2008). CoMFA and CoMSIA studies on thiazolidin-4-one as anti-HIV-1 agents. Journal of Molecular Graphics and Modelling. 27(6). 735–743. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shenghua Gao Breakdown of academic impact, for papers by Gladys Mbemba Breakdown of academic impact, for papers by Giuliana Cuzzucoli Crucitti Breakdown of academic impact, for papers by Norman M. Gray Breakdown of academic impact, for papers by Yuan Chu Breakdown of academic impact, for papers by Antonella De Montis Breakdown of academic impact, for papers by Guang‐Jin Im Breakdown of academic impact, for papers by Da Feng Breakdown of academic impact, for papers by Zhao Dang
Rankless by CCL
2026